Eczema Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages | Major Companies- GlaxoSmithKline, AstraZeneca, and Others

DelveInsight's, Eczema Pipeline Insight 2023 report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Eczema Pipeline Insight 2023 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Eczema pipeline landscape is provided which includes the disease overview and Eczema treatment guidelines. The assessment part of the report embraces, in depth Eczema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key highlights of the Eczema Pipeline Analysis Report
• The report provides detailed insights about companies that are developing therapies in the Eczema
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eczema
• Eczema companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Eczema Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eczema

The report is built using data and information traced from the researcher proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample of the Eczema Pipeline Report- https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Eczema Overview
Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the ""itch that rashes"" due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults. About 60% of cases will develop within the first year of life. The prevalence of atopic dermatitis is more common in rural rather than urban areas. This incidence which emphasizes the link to lifestyle and environment factors in the mechanisms of AD. Symptoms of eczema include: A red rash or red patches of skin, especially inside the folds of the elbows and knees, itching, dry skin, which can cracck and possibly bleed.

Eczema Pipeline Therapeutic Analysis
There are approx. 100+ key companies which are developing the therapies for Eczema. The companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.
Eczema Emerging Drugs

Amlitelimab: Kymab
Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of 'pro-inflammatory' effector T cells and promoting expansion of 'anti-inflammatory' regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.

BX 005: BiomX
BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

LP 0145: LEO Pharma
LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

Eczema Pipeline Companies
• Kymab
• BiomX
• LEO Pharma
• GlaxoSmithKline
• Arjil Pharmaceuticals
• SCM Lifescience
• Sun Pharmaceutical Industries
• Brickell Biotech Inc
• Dermira
• AstraZeneca
• Kyowa Kirin
• UCB Biopharma
• Arcutis Biotherapeutics

Eczema Pipeline Phases
DelveInsight's report covers around 100+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request Sample of the Eczema Pipeline, Emerging Drugs, Ongoing Clinical Trials Report- https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Introduction
2. Executive Summary
3. Eczema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eczema- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Amlitelimab: Kymab
10. Early Stage Products (Phase I)
11. Preclinical and Discovery Stage Products
12. Inactive Products
13. Eczema Key Companies
14. Eczema Key Products
15. Eczema- Unmet Needs
16. Eczema- Market Drivers and Barriers
17. Eczema- Future Perspectives and Conclusion
18. Eczema Analyst Views
19. Eczema Key Companies
20. Appendix

Got Queries? Find out the related information on Eczema Mergers and acquisitions, Eczema Licensing Activities @ Eczema Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.